Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nuvigil Labeling Will Likely Include Safety Information From Sparlon Clinical Trials

This article was originally published in The Pink Sheet Daily

Executive Summary

Cephalon’s follow-on product gets “approvable” letter as FDA considers common labeling for Provigil, Sparlon and Nuvigil.

You may also be interested in...



Nuvigil Draft Label Warning Includes Both Modafinil And Its Follow-On

Cephalon’s follow-on to the sleep disorder agent Provigil could be on the market by summer, despite “approvable” letter announced March 30.

Nuvigil Draft Label Warning Includes Both Modafinil And Its Follow-On

Cephalon’s follow-on to the sleep disorder agent Provigil could be on the market by summer, despite “approvable” letter announced March 30.

Unsettling Settlements: FTC Alarmed By Increasing Brand/Generic Deals

The Federal Trade Commission notes the threat of authorized generics, as well as its appeals court loss in the K-Dur case, as reasons for the jump in settlements.

Related Content

Topics

UsernamePublicRestriction

Register

PS064191

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel